What is Formation Bio?
Formation Bio distinguishes itself in the pharmaceutical sector by employing a technology-driven approach to radically enhance drug development efficiency. Its proprietary platform is engineered to optimize critical aspects of clinical trials, leading to more streamlined trial designs, accelerated completion timelines, and superior data quality. The company's strategy involves acquiring clinical-stage drugs from other pharmaceutical and biotech entities, with the objective of expediting their development to unlock greater value per program and, more importantly, to hasten the delivery of novel therapies to patients.
How much funding has Formation Bio raised?
Formation Bio has raised a total of $372M across 1 funding round:
Series D
$372M
Series D (2024): $372M with participation from Emerson Collective, Sanofi, Sequoia Capital, and Andreessen Horowitz
Key Investors in Formation Bio
Emerson Collective
Emerson Collective is an organization that invests in purpose-driven entrepreneurs and innovators, aiming to foster human flourishing by addressing complex challenges in education, economic mobility, immigration, and the environment.
Sanofi
Sanofi is a global biopharmaceutical company dedicated to improving lives through scientific innovation, focusing on discovering, developing, and delivering medicines and vaccines across various therapeutic areas.
Sequoia Capital
Sequoia Capital is a venture capital firm that takes a long-term view, acting as an active partner to entrepreneurs and management teams, with a track record of investing in global market leaders.
What's next for Formation Bio?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions Formation Bio for an accelerated growth phase. This backing is expected to fuel the expansion of its technology platform and the advancement of its drug development pipeline. The company's focus on efficiency and speed in clinical trials suggests a strategic intent to capture market share by reducing the time and cost associated with bringing new drugs to market. Future developments will likely center on the successful progression of its acquired clinical-stage assets through further development and regulatory pathways, potentially leading to significant value realization and enhanced patient outcomes.
See full Formation Bio company page
